JP6913459B2 - オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー - Google Patents

オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー Download PDF

Info

Publication number
JP6913459B2
JP6913459B2 JP2016531859A JP2016531859A JP6913459B2 JP 6913459 B2 JP6913459 B2 JP 6913459B2 JP 2016531859 A JP2016531859 A JP 2016531859A JP 2016531859 A JP2016531859 A JP 2016531859A JP 6913459 B2 JP6913459 B2 JP 6913459B2
Authority
JP
Japan
Prior art keywords
cto
signature
pathway
response
pharmacodynamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016531859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526908A5 (enExample
JP2016526908A (ja
Inventor
ラシダ エイ カルマリ
ラシダ エイ カルマリ
Original Assignee
タクティカル セラピューティクス インコーポレイテッド
タクティカル セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タクティカル セラピューティクス インコーポレイテッド, タクティカル セラピューティクス インコーポレイテッド filed Critical タクティカル セラピューティクス インコーポレイテッド
Publication of JP2016526908A publication Critical patent/JP2016526908A/ja
Publication of JP2016526908A5 publication Critical patent/JP2016526908A5/ja
Application granted granted Critical
Publication of JP6913459B2 publication Critical patent/JP6913459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2016531859A 2013-08-02 2014-07-30 オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー Active JP6913459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (3)

Publication Number Publication Date
JP2016526908A JP2016526908A (ja) 2016-09-08
JP2016526908A5 JP2016526908A5 (enExample) 2019-02-14
JP6913459B2 true JP6913459B2 (ja) 2021-08-04

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531859A Active JP6913459B2 (ja) 2013-08-02 2014-07-30 オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー

Country Status (9)

Country Link
US (1) US10378059B2 (enExample)
EP (1) EP3027776B1 (enExample)
JP (1) JP6913459B2 (enExample)
KR (1) KR102389934B1 (enExample)
CN (1) CN105531380B (enExample)
AU (1) AU2014296212B2 (enExample)
CA (1) CA2919690C (enExample)
IL (1) IL243894B (enExample)
WO (1) WO2015017545A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227205C (en) * 1995-07-21 2007-05-01 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
SI1504126T1 (sl) 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
AU2008232732A1 (en) 2007-03-28 2008-10-09 Medarex, Inc. Methods of gene amplification and expression
JP2011515088A (ja) * 2008-03-22 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 増殖因子シグナル伝達経路レギュレーション状態を評価するための方法及び遺伝子発現サイン
KR101597338B1 (ko) * 2009-09-04 2016-02-24 탁티칼 떼라페우틱스 인크. 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
JP6355555B2 (ja) * 2011-04-01 2018-07-11 キアゲン Ｗｎｔ／ｂ−カテニンシグナル伝達経路に関する遺伝子発現シグネチャーおよびその使用

Also Published As

Publication number Publication date
KR20160030535A (ko) 2016-03-18
WO2015017545A1 (en) 2015-02-05
KR102389934B1 (ko) 2022-04-21
CN105531380A (zh) 2016-04-27
US20150038349A1 (en) 2015-02-05
US10378059B2 (en) 2019-08-13
AU2014296212A1 (en) 2016-02-25
EP3027776C0 (en) 2024-02-07
EP3027776B1 (en) 2024-02-07
IL243894B (en) 2020-06-30
CA2919690A1 (en) 2015-02-05
JP2016526908A (ja) 2016-09-08
IL243894A0 (en) 2016-04-21
AU2014296212B2 (en) 2020-10-22
CA2919690C (en) 2021-11-02
EP3027776A4 (en) 2017-03-08
HK1220493A1 (en) 2017-05-05
EP3027776A1 (en) 2016-06-08
CN105531380B (zh) 2021-07-13

Similar Documents

Publication Publication Date Title
Paccez et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Menyhárt et al. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
Tamborini et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
Schulze et al. RELN signaling modulates glioblastoma growth and substrate‐dependent migration
Cesari et al. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
Liu et al. CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma
Shi et al. CKS1B as drug resistance-Inducing gene—a potential target to improve cancer therapy
JP2015110669A (ja) ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
Aref et al. Medulloblastoma: recurrence and metastasis
Wang et al. Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma
Fiala et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
He et al. Exploring PANoptosis in breast cancer based on scRNA-seq and bulk-seq
Ramaglia et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas
Ji et al. HTRA3 is a prognostic biomarker and associated with immune infiltrates in gastric cancer
Tomasini et al. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated with Chemotherapy for Non–Small-Cell Lung Cancer
Yang et al. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer
Lu et al. Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression
Yang et al. Circulating miRNA expression profiling and target prediction in patients receiving dexmedetomidine
Li et al. BPTF drives gastric cancer resistance to EGFR inhibitor by epigenetically regulating the C‐MYC/PLCG1/Perk Axis
JP6913459B2 (ja) オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー
Lin et al. Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A
Tufail et al. Wnt3a is a promising target in colorectal cancer
Erkin et al. Integrative analysis for identification of therapeutic targets and prognostic signatures in non-small cell lung cancer
Liu et al. Bioinformatics analysis of key biomarkers for bladder cancer
Lu et al. RETRACTED ARTICLE: Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181025

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190912

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190924

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191024

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191028

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191213

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191223

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200608

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210301

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210603

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210701

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210712

R150 Certificate of patent or registration of utility model

Ref document number: 6913459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250